Chongqing Peg-Bio Biopharm Co., Ltd.

  • CN
  • 2023
    On CPHI since
Contact info
Meet us at

CPHI & PMEC China 2025

Shanghai New International Expo Center
24 Jun 2025 - 26 Jun 2025

Products from Chongqing Peg-Bio Biopharm Co., Ltd. (1)

  • Semaglutide Intermediate (Recombinant)

    Product Semaglutide Intermediate (Recombinant)

    Semaglutide is a new 2nd Generation GLP-1RA drug developed by Novo Nordisk. In Dec. 2019, Semaglutide injection (brand name: Ozempic, 4mg/3ml) was approved by FDA to improve glycemic control in adults with type 2 diabetes. In Jun. 2021, Semaglutide injection (brand name: Wegovy, 2.4mg/dose) was approved by...

Recently Visited